Clinical trial Recruiting at 1 site Phase 4 Interventional Ages 18 to 70

Comparing morning and bedtime dosing of blood pressure medication

Official title: Morning Versus Bedtime Dosing of Antihypertensive Medication in Grade 1 Day-night Hypertension: a Multicenter Randomized Controlled Trial (Dosing-Time Trial)

Run by Shanghai Institute of Hypertension · NCT05089448 · Data updated 2026-11-12

This study is testing whether taking blood pressure medication in the morning or at bedtime works better to lower blood pressure in people with high blood pressure who haven't been treated before.

More Hypertension trials

Quick facts

PhasePhase 4
Study typeInterventional
Ages18 Years to 70 Years
SexAll
Enrollment300 (estimated)
SponsorShanghai Institute of Hypertension
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJanuary 28, 2021
Main results expectedJune 30, 2026
Study endsSeptember 30, 2026
Registry record updatedJanuary 6, 2025
Trial IDNCT05089448 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18-70 with untreated hypertension or those who have stopped antihypertensive medications for at least two weeks.

Probably not a fit

Patients with secondary hypertension, obstructive sleep apnea, or other conditions affecting nighttime blood pressure may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effects of morning versus bedtime dosing of antihypertensive medications on blood pressure levels in patients with hypertension. It will utilize both ambulatory and home blood pressure monitoring to assess nighttime, daytime, and 24-hour blood pressure reductions. The study will involve a multicenter randomized design, focusing on the potential differences in blood pressure control and target organ protection based on the timing of medication administration. The trial will include patients aged 18-70 who have not previously been treated for hypertension.

Why it matters

Potential benefit: If successful, this study could lead to improved blood pressure management strategies that enhance cardiovascular health.

How similar studies have gone: Previous studies have indicated the importance of nighttime blood pressure control, but this specific approach comparing dosing times in Chinese patients is novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Male or female patients aged 18-70 years old;
2. Never treated for hypertension or stopped using antihypertensive drugs for at least 2 weeks;
3. In the two screenings,the clinical systolic BP should be in the range of 140-159 mmHg, the diastolic BP \< 100 mmHg;
4. The average 24-hour systolic BP ≥130mmHg, daytime systolic BP ≥ 135 mmHg, and nighttime systolic BP ≥ 120 mmHg;
5. The average of bilateral brachial-ankle pulse wave velocity ≥14m/s;
6. Be willing to participate in the trial, sign the informed consent form, and be able to visit doctors by himself or herself.

Exclusion Criteria:

1. Secondary hypertension;
2. Concomitant obstructive sleep apnea (STOP-BANG score ≥ 5), insomnia, Parkinson's syndrome, or nocturnal polyuria and other diseases that affect nighttime BP;
3. Need to work at night;
4. Ambulatory BP monitoring was invalid (\<70% valid readings, or \<20 daytime readings or \<7 nighttime readings);
5. Concomitant diseases that need taking medications influencing BP;
6. Coronary heart disease, myocardial infarction or stroke within recent 6 months;
7. Atrial fibrillation or frequent arrhythmia;
8. Abnormal liver function exemplified as an increased alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin (TBL) over the double of the upper limit of normal range; abnormal renal function exemplified as a serum creatinine ≥176 µmol/L; and plasma potassium ≥5.5 mmol/L or ≤3.5mmol/L;
9. Pregnant or lactating women;
10. Contraindications of angiotensin II receptor blocker or calcium channel blocker;
11. Other concomitant diseases which are considered not suitable to participate in the trial, such as thyroid diseases, acute infectious diseases, chronic mental diseases, tumor, etc.

Where it's running

  • Ruijin Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.